To characterize airway responses in a population sample, respiratory symptoms, smoking habits, and changes in FEV1 (DELTAFEV1) to inhaled methacholine (maximal cumulative dose of 196 mumol or maximal decrease in Fev1 of 50%) were recorded in 201 subjects. From each dose-response curve the plateau (DELTAFev1 less-than-or-equal-to 5% over two or more dose steps) response, the maximal response (average of responses on the plateau or maximal DELTAFEV1 when no plateau was present), slope, and PD20 (dose required to cause DELTAFEV1 > 20%) were derived. The pattern of dose-response curves was a continuous change from being flat (maximal DELTAFEV1 less-than-or-equal-to 5%), becoming steeper with a plateau that occurred at a greater change In FEV1 as the curves were shifted more to the left, to being the steepest without a plateau response. Maximal DELTAFEV1 was significantly related to the PD20 (r = -0.64, p < 0.001) and the slope (r = 0.63, p < 0.001). A history of doctor-diagnosed asthma or wheeze in the last 12 months was related to the level of the maximal DELTAFEV1 and to PD20. Likelihood ratios [LR = sensitivity/(1 - specificity)] for asthma or wheeze were higher for a maximal DELTAFEV1 of 50% plus a PD20 of 4-mumol (LR = 6.5) or 1 mumol (LR = 7) than for either alone. Subjects without reported asthma or wheeze more often had a plateau on the dose-response curve (76%) than those with a positive history (49%, p < 0.001). In subjects with a maximal DELTAFEV1 < 50%, those without a plateau more often reported asthma or wheeze and usual cough and were more often current smokers than those with a plateau. These results show that the frequency of asthma symptoms is related to both the degree of maximal airway narrowing and the PD20 and is less in subjects with a plateau response indicating limitation of airway narrowing. The findings support the hypothesis that asthma results from the loss of factors that usually limit maximal airway narrowing.